Early Expression Profile of Inflammatory Markers and Kidney Allograft Status

McDaniel, D. Olga; Rigney, Debbie; McDaniel, Kori; Windham, W. Jordan; Hawxby, Alan; Butt, Fauzia

doi:10.1097/00007890-201211271-00107

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, Dessing et al () detected higher expression of TLR1/2/4/7 and 8 in acute rejection biopsy samples compared to the stable grafts; therefore, they proposed these molecules as prognostic and diagnostic biomarkers. Moreover, McDaniel et al () evaluated post‐transplant expression of TLR2 and TLR4 in recently transplanted patients and found a significant negative association between expression levels of these genes and glomerular filtration rate (GFR) in recipients. Our study also demonstrated elevated levels of TLR2 expression in PBMC samples of antibody‐mediated acute rejection patients but this finding was not statistically significant possibly because of limited number of samples or outlier cases.…”

Section: Discussionmentioning

confidence: 99%

TLR‐2, TLR‐4 and MyD88 genes expression in renal transplant acute and chronic rejections

Sharbafi

Assadiasl

Pour-Reza-Gholi

et al. 2019

Int J Immunogenetics

View full text Add to dashboard Cite

Background Graft rejection due to alloreactivity is still the main obstacle to successful renal transplantation. Toll‐like receptors (TLRs), which are significantly involved in initiating inflammation, triggering innate immunity, occurrence of ischaemia reperfusion injury (IRI) and subsequent deterioration of allograft function, are of interest in molecular diagnosis of graft rejection. Methods In present research, we have evaluated the mRNA expressions of TLR‐4, TLR‐2 and myeloid differentiation primary response gene 88 (MyD88) in peripheral blood mononuclear cells (PBMCs) and biopsy samples of 26 stable graft function (SGF), 14 acute T‐cell‐mediated rejection (ACMR), six acute antibody‐mediated rejection (AAMR), 10 chronic T‐cell‐mediated rejection (CCMR) and four chronic antibody‐mediated rejection (CAMR) cases of renal transplant recipients, using TaqMan detector real‐time polymerase chain reaction (RT‐PCR). Results It was found that TLR4 mRNA level was significantly elevated in PBMCs of both ACMR (P.v: 0.025) and CCMR (P.v: 0.007) cases, while TLR2 gene was upregulated only in PBMCs of ACMR (P.v: 0.024). Moreover, MyD88 expression was increased in biopsy samples of all rejection groups AAMR (P.v: 0.032), ACMR (P.v: 0.002), CAMR (P.v: 0.038) and CCMR (P.v: 0.013) and could distinguish them from stable grafts with AUC (area under curve) of 0.81, 0.80, 0.83 and 0.77, respectively. Conclusion These data showed that MyD88 gene upregulation in renal tissue could have diagnostic value and increased level of TLR4 mRNA in PBMCs could be suggestive of cell‐mediated rejections. Therefore, monitoring the expression level of inflammatory signalling genes might be useful in predicting allograft rejection.

show abstract

Section: Discussionmentioning

confidence: 99%

TLR‐2, TLR‐4 and MyD88 genes expression in renal transplant acute and chronic rejections

Sharbafi

Assadiasl

Pour-Reza-Gholi

et al. 2019

Int J Immunogenetics

View full text Add to dashboard Cite

show abstract

“…These results indicate that IL-10 is involved in the interaction between immunologic processes that maintain graft tolerance versus allograft rejection [147,156]. In general, the microenvironment of the tolerant allograft can reveal a decrease in pro-inflammatory mediators (IFN-γ, TNF-α) and an increase in the anti-inflammatory mediator IL-10, as well as increased expression of the master regulator of Tregs, FoxP3 [157].…”

Section: Principal Immune Conditionsmentioning

confidence: 96%

“…Early-stage infection IL-10 synthesis can also involve the neutrophils, because inhibition of IL-10 signaling abrogated the increase in Leshmania parasite loads in BALB/c mice during the first week [89]. Apart from acute phase infections, the IL-10 involvement during the first week is observed even in intracellular pathogens, tumors, and transplants, which demonstrate implication of PMCs, NK, and CD4+ T cells in the IL-10 synthesis [130,156,158,165,166]. Increased IL-10 production by CD4CD25FoxP3+ T cells along few weeks was observed in a time-dependent manner during melanoma tumor growth in mice, while the initial association of IL-10 production with migration of macrophages, DCs, and neutrophils following peritoneal scaffold implantation was replaced by association with T lymphocytes that became prevalent by day 14 [124,142].…”

Section: Il-10-an Indicator and Time-dependent Effector Of Immunity Smentioning

confidence: 98%

“…In this context, a wide range of cytokines can mediate the rescue tumor growth, as well as the liver and renal transplant rejection independently to (and in presence of) increased Btolerogenic^IL-10 level [120,124,130,132,134,149,156,158]. This turn-around of immune system action is achieved through mobilization and activation of FoxP3+ Tregs, myeloid-derived suppressor cells, tumor-associated macrophages, and fibroblasts, all of which suppress CD8+ T and NK cells at least in the early stages of Bimmune evasion^ [120,124,134].…”

Section: Il-10 Does Not Necessarily Decide the Direction Of Immunementioning

confidence: 99%

See 1 more Smart Citation

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Mingomataj

Bakiri

2015

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

The interleukin-10 (IL-10) is generally considered as the most important cytokine with anti-inflammatory properties and one of the key cytokines preventing inflammation-mediated tissue damage. In this respect, IL-10 producing cells play a crucial role in the outcome of infections, allergy, autoimmune reactions, tumor development, and transplant tolerance. Based on recent findings with regard to the mentioned clinical conditions, this review attempts to shed some light on the IL-10 functions, considering this cytokine as inherent inducer of the switching immunity. While acute infections and vaccinations are associated by IL-10 enhanced during few weeks, chronic parasitoses, tumor diseases, allergen-specific immunotherapy, transplants, and use of immune-suppressor drugs show an increased IL-10 level along months or years. With regard to autoimmune pathologies, the IL-10 increase is prevalently observed during early stages, whereas the successive stages are characterized by reaching of immune equilibrium independently to disease's activity. Together, these findings indicate that IL-10 is mainly produced during transient immune conditions and the persistent IL-10-related effect is the indication/prediction (and maybe effectuation) of the switching immunity. Actual knowledge emphasizes that any manipulation of the IL-10 response for treatment purposes should be considered very cautiously due to its potential hazards to the immune system. Probably, the IL-10 as potential switcher of immunity response should be used in association with co-stimulatory immune effectors that are necessary to determine the appropriate deviation during treatment of respective pathologies. Hopefully, further findings would open new avenues to study the biology of this "master switch" cytokine and its therapeutic potential.

show abstract

“…The published results of investigations are rather contradictory [21,32]. Many methods used (for instance, moleculargenetic) are expensive [14,17] for routine clinical diagnosis.…”

mentioning

confidence: 99%

Untitled

2015

COT

View full text Add to dashboard Cite

The most effective method of treatment of the patients at terminal stage of chronic kidney disease is the donor kidney allotransplantation. The main problem that determines the length and quality of patient's life remains to be chronic renal allograft dysfunction (RAD) [22,24]. There are specific (immune) and non-specific (non-immune) variants of chronic RAD that is accompanied with injuries of the nephron glomeruli or channels [24]. Predominantly these are: antigen-mediated rejection, recurrent and de novo globulomerulon nephritis and nephotoxicity of immunosupressants [22,24] which require specific therapy and differ in terms of the prognosis. From the clinical viewpoint, apart from differential diagnosis of the variants of RAD the active (potentially curable) phase of pathological processes in the renal allotransplantat (RAT) should be distinguished from the inactive one [18].For diagnosis of RAD the use has been made of invasive [18] and/ or non-invasive [1,32] approaches, each of them having its advantages and disadvantages. The commonly used non-invasive indicator of RAT function, serum creatinine (Cr) concentration, is the relatively less sensitive marker of the dysfunction [32] which does not evidence for pathological process activity. The non-invasive biochemical markers of injuries of both native kidneys and RAT can be the followings: enzymes ABSTRACT The most investigations of the biomarkers of renal allograft dysfunction (RAD) are limited by early post-operational period and are aimed at diagnosis of acute rejection of renal transplant.This work has aimed to establish additional characteristics of chronic RAD by using non-invasive biomarkers of the blood serum and urine. MATERIALS AND METHODS. 79 patients aged 16 to 59 years (47 men and 32 women) took part in our retrospective study. The alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamil transferase (GGT), alkaline phosphatase (ALP), N-acetyl-β-Dglucosaminidase (NAG); interleukins (IL-2, IL-8, IL-10) and beta-2-microglobulin were evaluated. RESULTS. Increased IL-10 and β2-MG

show abstract

Early Expression Profile of Inflammatory Markers and Kidney Allograft Status

Cited by 5 publications

References 0 publications

TLR‐2, TLR‐4 and MyD88 genes expression in renal transplant acute and chronic rejections

TLR‐2, TLR‐4 and MyD88 genes expression in renal transplant acute and chronic rejections

Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response

Untitled

Contact Info

Product

Resources

About